IsoPlexis is empowering the ability to uncover sources of resistance to solid tumor therapies and translate that data to therapeutic insight
By finding the small groups of highly dysfunctional tumor and functional immune cells that are driving resistance, IsoPlexis is working with leaders to address challenges across cancers, related to understanding sources of progression with an ability to translate this information to therapeutic insight.
Solid Tumor & Oncology
Join us to learn more about how we are accelerating solid tumor & oncology programs across the discover-optimize-predict continuum with our unique cellular analysis metrics
Our SNAI has identified drug-induced resistance in a correlative manner that can be targeted therapeutically
IsoPlexis' heterogeneity index is predicting cancer resistance, enabling development of novel combination treatments
Our products are uncovering correlations of TIL function in solid tumors, which can be used for targeting
on our datasets >[/ce_button]
Single-Cell Analysis Resolves the Cell State Transition and Signaling Dynamics Associated with Melanoma Drug-Induced Resistance. Su Y, Wei W, Robert L, Xue M, Tsoi J, Garcia-Diaz A, Homet Moreno B, Kim J, Ng R, Lee JW, Koya RC, Comin-Anduix B, Graeber TG, Ribas A, and Heath JR. Proc. Natl. Acad. Sci. 114 (52) 13679-13684 (2017).
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, and Gini B. Cancer Cell, 29:4 563-573 (2016).
Single-cell PSI of CD8+ TILs in melanoma shows uniquely sensitive correlates with response to anti-PD-1/CTLA4 therapy, where histology and serum cytokines were unable to detect significant associations. Mackay S, Flynn B, Morse K, Paczkowski P, Chen J, Liu D, Bacchiocchi A, Heath JR, Fan R, Sznol M, Halaban R, Zhou J. Presented at SITC Annual Meeting 2018.
Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy. Mackay S, Flynn B, Morse K, Paczkowski P, Bacchiocchi A, Heath JR, Fan R, Halaban R, and Zhou J. Presented at TRCCC Annual Meeting 2018.
Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy. Mackay S, Flynn B, Morse K, Paczkowski P, Bacchiocchi A, Fan R, Halaban R, and Zhou J. Journal of Clinical Oncology, 35 (9), Suppl. 7S (2017).